Key result
CalDAG-GEFI deficiency in mice virtually abolished arterial thrombosis while maintaining hemostatic function, suggesting a better safety profile than P2Y12 inhibitors like clopidogrel.
Why the study?
Does genetic deletion of CalDAG-GEFI reduce thrombosis and preserve hemostasis compared to clopidogrel in mice?
Does genetic deletion of CalDAG-GEFI reduce thrombosis and preserve hemostasis compared to clopidogrel in mice?
Answers are grounded in this paper and cite their sources.
Inhibition of CalDAG-GEFI may provide strong protection from atherothrombotic complications with a better safety profile (less bleeding) than P2Y12 inhibitors like clopidogrel.
Two major pathways contribute to Ras-proximate-1-mediated integrin activation in stimulated platelets. Calcium and diacyglycerol-regulated guanine nucleotide exchange factor I (CalDAG-GEFI, RasGRP2) mediates the rapid but reversible activation of integrin αIIbβ3, while the adenosine diphosphate receptor P2Y12, the target for antiplatelet drugs like clopidogrel, facilitates delayed but sustained integrin activation. To establish CalDAG-GEFI as a target for antiplatelet therapy, we compared how each pathway contributes to thrombosis and hemostasis in mice. Ex vivo, thrombus formation at arterial or venous shear rates was markedly reduced in CalDAG-GEFI(-/-) blood, even in the presence of exogenous adenosine diphosphate and thromboxane A(2). In vivo, thrombosis was virtually abolished in arterioles and arteries of CalDAG-GEFI(-/-) mice, while small, hemostatically active thrombi formed in venules. Specific deletion of the C1-like domain of CalDAG-GEFI in circulating platelets also led to protection from thrombus formation at arterial flow conditions, while it only marginally increased blood loss in mice. In comparison, thrombi in the micro- and macrovasculature of clopidogrel-treated wild-type mice grew rapidly and frequently embolized but were hemostatically inactive. Together, these data suggest that inhibition of the catalytic or the C1 regulatory domain in CalDAG-GEFI will provide strong protection from athero-thrombotic complications while maintaining a better safety profile than P2Y12 inhibitors like clopidogrel.
No takes yet. Share an insight, caveat, or question.
Stolla et al. (2010) studied Thrombosis and hemostasis. CalDAG-GEFI deficiency/inhibition vs. Clopidogrel (P2Y12 inhibition) / wild-type was evaluated on Thrombus formation and hemostasis. CalDAG-GEFI deficiency in mice virtually abolished arterial thrombosis while maintaining hemostatic function, suggesting a better safety profile than P2Y12 inhibitors like clopidogrel.
Synapse has enriched 10 related papers. Consider them for comparative context: